Document Detail

Design and Biological Evaluation of Cell-Penetrating Peptide-Doxorubicin Conjugates as Prodrugs.
MedLine Citation:
PMID:  23301519     Owner:  NLM     Status:  Publisher    
Doxorubicin (Dox) is a hydrophilic anticancer drug that has short retention time due to the efficient efflux in some cancer cells (e.g., ovarian adenocarcinoma SK-OV-3). Cyclic [W(RW)4] and the corresponding linear peptide (RW)4 were conjugated with Dox through an appropriate linker to afford cyclic [W(RW)4]-Dox and linear (RW)4-Dox conjugates to enhance the cellular uptake and cellular retention of the parent drug for sustained anticancer activity. Comparative antiproliferative assays between covalently (cyclic [W(RW)4]-Dox and linear (RW)4-Dox) and the corresponding noncovalent physical mixtures of the peptides and Dox was performed. Cyclic [W(RW)4]-Dox inhibited the cell proliferation of human leukemia (CCRF-CEM) (62-73%), ovarian adenocarcinoma (SK-OV-3) (51-74%), colorectal carcinoma (HCT-116) (50-67%), and breast carcinoma (MDA-MB-468) (60-79%) cells at a concentration of 1 μM after 72-120 h of incubation. Cyclic [W(RW)4]-Dox exhibited higher antiproliferative activity than linear (RW)4-Dox in all cancer cells with the highest activity observed after 72 h. Flow cytometry analysis showed 3.6 folds higher cellular uptake of cyclic [W(RW)4]-Dox than Dox alone in SK-OV-3 cells after 24 h incubation. The cellular hydrolysis study showed that 99% of cyclic [W(RW)4]-Dox was hydrolyzed intracellularly within 72 h and released Dox. These data suggest that cyclic [W(RW)4]-Dox can be used as a potential prodrug for improving the cellular delivery and retention of Dox.
Amir Nasrolahi Shirazi; Rakesh K Tiwari; Bhupender S Chhikara; Dindyal Mandal; Keykavous Parang
Related Documents :
24223799 - Alternative signaling pathways as potential therapeutic targets for overcoming egfr and...
24738969 - Positive correlation between the efficiency of induced pluripotent stem cells and the d...
20818069 - Proteomics of apoptosis of multiple myeloma cells induced by proteasome inhibitor ps-341.
22289989 - Integrated genomic analyses identify wee1 as a critical mediator of cell fate and a nov...
24273639 - Synthesis and biological activity of nosh-naproxen (avt-219) and nosh-sulindac (avt-18a...
24212099 - Technical advance: a new cell preparation strategy that greatly improves the yield of v...
12036189 - Interstitial cells of cajal and purinergic signalling.
22252099 - Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inh...
18226069 - Testicular dysgenesis syndrome and leydig cell function.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-9
Journal Detail:
Title:  Molecular pharmaceutics     Volume:  -     ISSN:  1543-8392     ISO Abbreviation:  Mol. Pharm.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101197791     Medline TA:  Mol Pharm     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Development of a Scale to Assess Knowledge about Suicide Postvention using Item Response Theory.
Next Document:  Pharmacokinetic evaluation of capecitabine in breast cancer.